Search Results

Addition of hemostatic patch complements Ethicon’s comprehensive Biosurgery portfolio and ability to address critical unmet needs in controlling bleeding.

The most common inflammatory skin disease causes scaly patches, blisters and severe itching, but it’s far more than just a cosmetic concern. Learn why Johnson & Johnson is focused on helping the millions living with this painful condition.

The chronic skin condition causes itchy and scaly patches, but it’s much more than simply a cosmetic concern. For World Psoriasis Day, take this quiz to test your psoriasis IQ—and learn why Johnson & Johnson is working on new and more effective treatments for this common autoimmune disease.

Nina Raver-Shapira, Ph.D., loves a challenge: The Johnson & Johnson scientist persisted for years to develop an innovative surgical patch that helps stop problematic bleeding during surgery—and she’s also a record-breaking elite athlete. For Women’s Equality Day, find out how she got her start, what achievements she’s most proud of and where she finds inspiration.

66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to demonstrate a standout combination of significant skin clearance (IGA 0/1) and a favorable safety profile in a once daily pill

It may look deceptively simple, but this newly FDA-approved tool can help stop patients from bleeding during surgery.

Up to 5 million people worldwide live with this complex autoimmune condition, which is more prevalent in women and has a greater disease severity in Latin Americans and patients of African ancestry. Learn how Johnson & Johnson is working to innovate treatments for autoimmune diseases.

ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously 84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16

The EVARREST® expanded indication now provides surgeons innovation offering superior hemostatic efficacy on the 1st-attempt[1]

Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with investigational icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD Topline results from Phase 3 ICONIC-ADVANCE 1&2 studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO These results pave the way to initiate the first-ever head-to-head study seeking to demonstrate the superiority of a pill versus injectable biologic in moderate-to-severe plaque PsO